Eisai Inc. submitted a supplemental New Drug Application for priority review to the U.S. FDA for the company’s antiepileptic drug Fycompa (perampanel) CIII as monotherapy and adjunctive use.
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention (CDC), Dr. Robert Redfield predicted the AIDS epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.
Sunovion Pharmaceuticals announced the submission of a new drug application to the U.S. FDA for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).
The FDA approved Amgen’s supplemental Biologic License Application for Blincyto (blinatumomab) to treat B-cell precursor acute lymphoblastic leukemia (ALL) under specific circumstances.
Starbucks Corp. and other coffee sellers must put a cancer warning on coffee sold in California, a Los Angeles judge ruled, possibly exposing the companies to millions of dollars in fines.
Arkansas’ attorney general joined the widening mass of litigation against opioid manufacturers, accusing three drugmakers of promoting addictive painkillers in ways that falsely denied or trivialized their risks.
Sandbox announced the opening of the independent, full-service agency’s new office space in Kansas City, Mo., uniting its two local locations under one roof.
Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.